Early Stages of Sea-Level Rise Lead To Decreased Salt Marsh Plant Diversity through Stronger Competition in Mediterranean-Climate Marshes - Fig 2 by Akana E. Noto (3623366)

Flow diagram of the study population. by Dina Evyana (18462048)

“…MetS was found in 64.3% of patients. Patients with a PASI score>10 had a significantly higher risk of metabolic syndrome compared to those with a score ≤ 10 (78.6% vs 50%, OR 3.667; 95% CI 1.413–9.514; <i>p</i> = 0.006). …”

Exercise training decreases 4-HNE modification of proteasome and re-establishes cardiac ubiquitin-proteasome system function in myocardial infarction-induced heart failure. by Juliane C. Campos (145308)

IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

“…Next, by means of IC₅₀ measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”

Psoriatic lesion in some of the hard-to-treat areas of the study population. by Dina Evyana (18462048)

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Image_3_Decrease of GSK-3β Activity in the Anterior Cingulate Cortex of Shank3b−/− Mice Contributes to Synaptic and Social Deficiency.TIF by Mengmeng Wang (540017)

“…From 4 weeks post-birth, neurons in Shank3b^−/− ACC exhibited an obvious decrease in spine density and stubby spines. The length and thickness of post-synaptic density (PSD), the expression of vesicular glutamate transporter 2 (vGlut2) and glutamate receptor 2 (GluR2), and the frequency of miniature excitatory post-synaptic currents (mEPSCs) were significantly reduced in Shank3b^−/−ACC. …”

Image_1_Decrease of GSK-3β Activity in the Anterior Cingulate Cortex of Shank3b−/− Mice Contributes to Synaptic and Social Deficiency.tif by Mengmeng Wang (540017)

“…From 4 weeks post-birth, neurons in Shank3b^−/− ACC exhibited an obvious decrease in spine density and stubby spines. The length and thickness of post-synaptic density (PSD), the expression of vesicular glutamate transporter 2 (vGlut2) and glutamate receptor 2 (GluR2), and the frequency of miniature excitatory post-synaptic currents (mEPSCs) were significantly reduced in Shank3b^−/−ACC. …”

Image_4_Decrease of GSK-3β Activity in the Anterior Cingulate Cortex of Shank3b−/− Mice Contributes to Synaptic and Social Deficiency.TIF by Mengmeng Wang (540017)

“…From 4 weeks post-birth, neurons in Shank3b^−/− ACC exhibited an obvious decrease in spine density and stubby spines. The length and thickness of post-synaptic density (PSD), the expression of vesicular glutamate transporter 2 (vGlut2) and glutamate receptor 2 (GluR2), and the frequency of miniature excitatory post-synaptic currents (mEPSCs) were significantly reduced in Shank3b^−/−ACC. …”

Image_2_Decrease of GSK-3β Activity in the Anterior Cingulate Cortex of Shank3b−/− Mice Contributes to Synaptic and Social Deficiency.TIF by Mengmeng Wang (540017)

“…From 4 weeks post-birth, neurons in Shank3b^−/− ACC exhibited an obvious decrease in spine density and stubby spines. The length and thickness of post-synaptic density (PSD), the expression of vesicular glutamate transporter 2 (vGlut2) and glutamate receptor 2 (GluR2), and the frequency of miniature excitatory post-synaptic currents (mEPSCs) were significantly reduced in Shank3b^−/−ACC. …”

Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells by Yang Li (7082)

“…Herein, a series of celastrol urea derivatives were developed based on its cocrystal structure with PRDX1, with the aim of pursuing a PRDX1-specific inhibitor. …”

Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

“…Compared to the type I PRMT inhibitor from our previous work (DCPR049_12), ZL-28-6 showed increased potency against CARM1 and decreased activity against other type I PRMTs. Moreover, ZL-28-6 showed better antiproliferation activities toward a series of solid tumor cells than DCPR049_12, indicating its broad spectrum of anticancer activity. …”

Association of metabolic syndrome and psoriasis severity. by Dina Evyana (18462048)

Sociodemographic characteristic of the study population. by Dina Evyana (18462048)

Baseline clinical characteristic of the study population. by Dina Evyana (18462048)

Prevalence of metabolic syndrome (MetS) in hard-to-treat psoriasis. by Dina Evyana (18462048)

The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

“…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”

Decreasing fitness over time observed following analysis of paired isolates obtained from acute HIV-1 infection subjects, measured using QPCR. by Alicia Arnott (242179)

Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

“…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC₅₀ value compared to cisplatin and low toxicity to normal cells. …”